TRex Bio, Inc. (NasdaqGS: TRXB)
Health Care · Biotechnology · US
$14.10
-1.05% today · +0.7% 1Y
TRex Bio, Inc. (NasdaqGS: TRXB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $379.60M and employs 60 people.
Over the last twelve months the share price has gained 0.7%, trading between 12.99 and 16.56.
Tweenvest scores TRex Bio, Inc. across four factors: quality 64/100, value 69/100. Its strongest factor is value.
TRXB price history
Key figures
- Market cap
- $379.60M
- Revenue (TTM)
- —
- P/E
- -120.74
- EPS
- -8.59
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $16.56
- 52-week low
- $12.99
- Avg volume (3M)
- —
- Shares outstanding
- 26.92M
- Employees
- 60
- Next earnings
- —
About TRex Bio, Inc.
Trex Bio, Inc. engages in the manufacture of immunotherapies for autoimmune and inflammatory diseases. It focuses on studying the regulation of tissue inflammation to develop breakthrough medicines. The company was founded by Houman Ashrafian, Adil Daud, Wilson Liao, Diane Mathis, Drew Pardoll, Michael Rosenblum, Alison Simmons, and Jim Wells in May 24, 2018 and is headquartered in South San Francisco, CA.
- ISIN
- US89531N1000
- Founded
- 2018
- Listed since
- Oct 9, 2026
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Beijing Kawin Technology Share-Holding Co., Ltd.SHSE: 688687 | $386.54M | CN¥15.41 | -1.85% |
| Opus Genetics, Inc.NasdaqCM: IRD | $384.68M | $3.98 | -1.97% |
| ARS Pharmaceuticals, Inc.NasdaqGM: SPRY | $383.01M | $3.81 | -3.54% |
| Avacta Group PlcAIM: AVCT | $379.77M | £0.59 | -4.22% |
| PureTech Health plcLSE: PRTC | $378.25M | £1.17 | -0.51% |
| Alector, Inc.NasdaqGS: ALEC | $378.15M | $2.54 | +3.67% |
| TransThera Sciences (Nanjing), Inc.SEHK: 2617 | $376.88M | HK$7.26 | -4.16% |
| Puma Biotechnology, Inc.NasdaqGS: PBYI | $373.26M | $7.22 | +0.98% |